Paris - Delayed Quote EUR

Novacyt S.A. (ALNOV.PA)

Compare
0.5870 -0.0210 (-3.43%)
As of 4:16 PM GMT+1. Market Open.
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
11,579.0000
11,579.0000
21,040.0000
92,603.0000
277,204.0000
Cost of Revenue
7,849.0000
7,849.0000
15,294.0000
64,377.0000
65,704.0000
Gross Profit
3,730.0000
3,730.0000
5,746.0000
28,226.0000
211,500.0000
Operating Expense
21,892.0000
21,892.0000
21,421.0000
26,811.0000
36,577.0000
Operating Income
-18,162.0000
-18,162.0000
-15,675.0000
1,415.0000
174,923.0000
Net Non Operating Interest Income Expense
1,865.0000
1,865.0000
918.0000
45.0000
-2,180.0000
Pretax Income
-28,568.0000
-28,568.0000
-20,053.0000
-5,660.0000
165,171.0000
Tax Provision
-768.0000
-768.0000
2,148.0000
349.0000
32,748.0000
Net Income Common Stockholders
-28,292.0000
-28,292.0000
-25,730.0000
-9,728.0000
132,423.0000
Diluted NI Available to Com Stockholders
-28,292.0000
-28,292.0000
-25,730.0000
-9,728.0000
132,423.0000
Basic EPS
-0.36
-0.40
-0.36
-0.14
1.94
Diluted EPS
-0.36
-0.40
-0.36
-0.14
1.94
Basic Average Shares
70,626.2480
70,626.2480
70,626.2480
70,626.2480
68,187.1010
Diluted Average Shares
70,626.2480
70,626.2480
70,626.2480
70,626.2480
68,187.1010
Total Operating Income as Reported
-29,516.0000
-29,516.0000
-23,393.0000
-3,916.0000
167,441.0000
Rent Expense Supplemental
340.0000
340.0000
477.0000
397.0000
337.0000
Total Expenses
29,741.0000
29,741.0000
36,715.0000
91,188.0000
102,281.0000
Net Income from Continuing & Discontinued Operation
-28,292.0000
-28,292.0000
-25,730.0000
-9,728.0000
132,423.0000
Normalized Income
-11,004.8880
-11,004.8880
-11,297.7500
1,863.6050
144,004.3642
Interest Income
735.0000
735.0000
779.0000
396.0000
46.0000
Interest Expense
682.0000
682.0000
458.0000
120.0000
1,601.0000
Net Interest Income
1,865.0000
1,865.0000
918.0000
45.0000
-2,180.0000
EBIT
-27,886.0000
-27,886.0000
-19,595.0000
-5,540.0000
166,772.0000
EBITDA
-18,243.0000
-18,243.0000
-11,677.0000
2,342.0000
174,968.0000
Reconciled Cost of Revenue
7,849.0000
7,849.0000
15,294.0000
64,377.0000
65,704.0000
Reconciled Depreciation
9,643.0000
9,643.0000
7,918.0000
7,882.0000
8,196.0000
Net Income from Continuing Operation Net Minority Interest
-27,800.0000
-27,800.0000
-22,201.0000
-6,009.0000
132,423.0000
Total Unusual Items Excluding Goodwill
-11,304.0000
-11,304.0000
-7,663.0000
-5,243.0000
-7,251.0000
Total Unusual Items
-5,509.0000
-5,509.0000
-2,507.0000
-1,224.0000
-1,483.0000
Normalized EBITDA
-12,734.0000
-12,734.0000
-9,170.0000
3,566.0000
176,451.0000
Tax Rate for Calcs
0.0000
0.0000
0.0003
0.0003
0.0002
Tax Effect of Unusual Items
-303.8880
-303.8880
-1,915.7500
-1,389.3950
-1,437.6358
12/31/2020 - 10/12/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALSGD.PA SpineGuard SA
0.2120
-4.33%
 
ALCAR.PA Carmat SA
1.1980
-2.92%
 
ACARIX.ST Acarix AB (publ)
0.3180
-0.47%
 
NSPR InspireMD, Inc.
2.5400
-4.15%
 
CHEMM.CO ChemoMetec A/S
428.60
-1.43%
 
AEMD Aethlon Medical, Inc.
0.3892
+0.31%
 
OPGN OpGen, Inc.
1.9500
0.00%
 
DCTH Delcath Systems, Inc.
9.94
+2.06%
 
INMD InMode Ltd.
17.85
-0.28%
 
PACB Pacific Biosciences of California, Inc.
1.6394
+4.42%